Comparison 61. NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
61.1 Participant assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
61.1.1 4 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.89, 1.15]
61.1.2 8 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.83, 1.03]
61.1.3 12 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.90, 1.16]
61.1.4 16 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.70, 1.01]
61.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)	1		Peto Odds Ratio (Peto, Fixed, 95% CI)	Subtotals only
61.3 Physician assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
61.3.1 4 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.89, 1.13]
61.3.2 8 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.86, 1.11]
61.3.3 12 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.88, 1.32]
61.3.4 16 weeks	1	220	Risk Ratio (M‐H, Random, 95% CI)	1.14 [0.83, 1.56]
61.4 Total adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
61.4.1 Total adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected